- Home
- IDA vs JAZZ Comparison
IDA vs JAZZ Comparison
Compare IDA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDA
- JAZZ
- Stock Information
- Founded
- IDA 1915
- JAZZ 2003
- Country
- IDA United States
- JAZZ Ireland
- Employees
- IDA N/A
- JAZZ N/A
- Industry
- IDA Electric Utilities: Central
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- IDA Utilities
- JAZZ Health Care
- Exchange
- IDA Nasdaq
- JAZZ Nasdaq
- Market Cap
- IDA 6.3B
- JAZZ 7.3B
- IPO Year
- IDA N/A
- JAZZ 2007
- Fundamental
- Price
- IDA $116.71
- JAZZ $110.32
- Analyst Decision
- IDA Buy
- JAZZ Strong Buy
- Analyst Count
- IDA 7
- JAZZ 13
- Target Price
- IDA $122.86
- JAZZ $182.00
- AVG Volume (30 Days)
- IDA 642.4K
- JAZZ 1.3M
- Earning Date
- IDA 07-31-2025
- JAZZ 07-30-2025
- Dividend Yield
- IDA 2.95%
- JAZZ N/A
- EPS Growth
- IDA 12.96
- JAZZ 49.21
- EPS
- IDA 5.63
- JAZZ 7.51
- Revenue
- IDA $1,810,154,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- IDA $5.60
- JAZZ $6.02
- Revenue Next Year
- IDA $9.80
- JAZZ $4.36
- P/E Ratio
- IDA $20.75
- JAZZ $14.68
- Revenue Growth
- IDA 1.37
- JAZZ 5.76
- 52 Week Low
- IDA $90.64
- JAZZ $95.49
- 52 Week High
- IDA $120.84
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- IDA 51.44
- JAZZ 52.19
- Support Level
- IDA $115.00
- JAZZ $105.38
- Resistance Level
- IDA $119.27
- JAZZ $110.48
- Average True Range (ATR)
- IDA 2.02
- JAZZ 3.38
- MACD
- IDA 0.27
- JAZZ 0.61
- Stochastic Oscillator
- IDA 76.98
- JAZZ 78.78
About IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.